SAN903

SAN903 is an investigational **small molecule** ion channel modulator being developed by **Saniona** for rare inflammatory and fibrotic disorders. It is described as a potential **first-in-class inhibitor of the calcium-activated potassium ion channel KCa3.1**, a channel expressed on multiple immune cell types and implicated in pathogenic immune activation and chronic inflammation. Publicly described target disease areas include **inflammatory bowel disease**, **chronic kidney disease**, and **idiopathic pulmonary fibrosis**. The program has been reported as **preclinical** and ready for clinical studies, but no approved brand name, dosage form, route of administration, or marketed formulation has been identified.